Industries / Health / Pharmaceuticals / Contract drug manufacturing
Quality and inspections
This is how drug companies and regulators check a contract maker: the written split of duties, the drug company's own audits, and inspections by regulators.
6
Milestones achieved, from 1970 to 2025.
1
To watch for: announced, not yet confirmed outside.
2
Open deliverables. Nobody has shipped them.
The road
AchievedWatch forOpen
Achieved
1970
Inspectors trust each other
In October 1970 the European Free Trade Association (EFTA) set up "The Convention for the Mutual Recognition of Inspections in Respect of the Manufacture of Pharmaceutical Products", the Pharmaceutical Inspection Convention (PIC). It let one member's regulator rely on another's inspection of a drug plant, and it came into force in 1971. EU law later blocked new members, so a looser PIC Scheme was formed on 2 November 1995. The two together are called PIC/S.
Credit
EFTA; PIC/S
2013
Outsourcing written into EU rules
Chapter 7 of the EU's good manufacturing practice (GMP) guide was rewritten as "Outsourced activities" and applied from 31 January 2013. A written contract between the "Contract Giver" and the "Contract Acceptor" must set out each party's duties, and the contract giver remains "ultimately responsible" for controlling the outsourced work. The rewrite followed ICH Q10, the shared guideline on a drug maker's quality system, which took legal effect in the EU on 1 June 2008.
Credit
European Commission; ICH
2016
Quality agreements defined
The FDA's guidance "Contract Manufacturing Arrangements for Drugs: Quality Agreements" (November 2016) describes a quality agreement: a written document saying which party does which manufacturing task. The guidance says the drug's owner and the contract facility are both bound by current good manufacturing practice (CGMP, the US rules), whatever the agreement says. The owner's quality unit approves or rejects what the contract facility makes. After finding problems at a contract plant, the FDA may inspect the owner too.
Credit
the FDA's drug, biologics and veterinary centres (CDER, CBER, CVM)
2017
US and EU share inspections
The part of the US–EU Mutual Recognition Agreement (MRA) that covers drug GMP came into force on 1 November 2017. Under it, each side's inspectors rely on reports from the other's inspections and need not inspect the same plant twice. The FDA recognised its first EU inspectorates that day and added the rest over the next two years, some with limits. Malta's, for example, does not cover sterile products. Animal medicines were added in May 2023.
Credit
FDA; European Commission; EU national inspectorates
2021
A vaccine plant fails
Emergent BioSolutions made COVID-19 vaccine ingredients at its Bayview plant in Baltimore under contracts with Johnson & Johnson (USD 482 million) and AstraZeneca (USD 174 million). In March 2021 the two vaccines were cross-contaminated, and the FDA ordered a halt to manufacturing from April to August 2021. A US House staff report of 10 May 2022 put the doses destroyed at nearly 400 million. It also found that AstraZeneca, Johnson & Johnson, the FDA and an outside consultant had all flagged problems before and during production, and that staff removed "hold tags" from batches before an FDA visit in February 2021.
Lessonaudit findings protect nothing until they are fixed; both clients had warned about Bayview months before the losses.
Credit
Emergent BioSolutions; the House Committee on Oversight and Reform and its Select Subcommittee on the Coronavirus Crisis
2025
Remote reviews kept after COVID
In June 2025 the FDA finalised its guidance on remote regulatory assessments (RRAs). These include requests for records, which a drug plant must answer under section 704(a)(4) of the US Food, Drug, and Cosmetic Act, and voluntary live video tours and teleconferences. The FDA first used them widely when COVID-19 stopped travel, and the guidance covers their use beyond the pandemic.
Credit
FDA
Watch for
Surprise inspections abroad
The FDA said on 6 May 2025 that it would make more of its inspections of foreign plants unannounced, building on pilots in India and China. Foreign firms had often had weeks of notice. By the FDA's own figures, published in August 2026, unannounced visits rose in India from 47% of 139 inspections in fiscal year 2025 to 87% of 76 so far in fiscal 2026, and in China from 19% of 192 to 61% of 114.
Achieved whenan outside auditor, such as the US Government Accountability Office (GAO), confirms the share for a full year and reports whether unannounced visits find serious problems more often.
Claimed by
FDA, May 2025 (figures August 2026)
Open
01
Score public quality agreements
A public set of real quality agreements between drug companies and contract makers, taken from exhibits filed with the US Securities and Exchange Commission (SEC). Each is scored against the items that the FDA's 2016 guidance and EU GMP Chapter 7 say an agreement should cover, such as change control, deviations, audits and who releases each batch. Then a test of whether AI models give the same scores as two people with GMP experience.
The briefCredit · unclaimed02
Owner or contractor, tagged
A tagged table of FDA warning letters about drug manufacturing that involve a contract arrangement. Each row says who received the letter (the drug's owner, a contract maker or a contract test lab), which duty failed (checking a supplier, change control, release testing), and quotes the sentence the tag came from.
The briefCredit · unclaimed
Open 01 · the brief
Score public quality agreements
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A public set of real quality agreements between drug companies and contract makers, taken from exhibits filed with the US Securities and Exchange Commission (SEC). Each is scored against the items that the FDA's 2016 guidance and EU GMP Chapter 7 say an agreement should cover, such as change control, deviations, audits and who releases each batch. Then a test of whether AI models give the same scores as two people with GMP experience.
Why it is still open
Quality agreements are usually private, but some are public. Alder BioPharmaceuticals filed its 73-page quality agreement with Sandoz, for making and testing a bulk drug substance, with its annual report in February 2019. An EDGAR full-text search for the phrase "this quality agreement" returned 376 filings on 20 November 2026, though many are supply contracts that only mention one. CUAD, a labelled set of 510 EDGAR contracts from The Atticus Project, marks 41 clause types that lawyers check in contract review. I found no labelled set for the duties GMP rules assign.
Built with what exists
SEC EDGAR full-text search; Python; a checklist written from the FDA guidance and Chapter 7; Claude; Gemini Decision 1, which scores up to 1,000 fixed-answer questions in one request (Note: "A thousand questions, one pass"); an open-weight model such as Mistral Large 4 (Note: "A trillion open parameters"); a spreadsheet for the human scores.
First step
Score the Alder–Sandoz agreement against the guidance's list, then sort the first 100 EDGAR hits into true quality agreements and contracts that only refer to one.
Done looks like
At least 50 agreements collected with source links, each scored by two people against the published checklist, the agreement between those two people reported, and at least three AI systems scored on how often they match the human score for each item.
Open 02 · the brief
Owner or contractor, tagged
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A tagged table of FDA warning letters about drug manufacturing that involve a contract arrangement. Each row says who received the letter (the drug's owner, a contract maker or a contract test lab), which duty failed (checking a supplier, change control, release testing), and quotes the sentence the tag came from.
Why it is still open
The letters are already gathered, but not tagged this way. One open dataset holds the full text of 6,428 warning letters from January 2018 to 10 August 2026. Another lists 2,713 inspections from January 2021 to October 2026 that the FDA classed "Official Action Indicated" (OAI). Neither marks the contract relationship. A text search of the first set for the FDA's stock wording, such as "FDA regards contractors as extensions of the manufacturer", finds it in 216 of the 1,739 letters that cite drug GMP rules, by this file's count.
Built with what exists
the two Hugging Face datasets; Python; a language model such as Claude to propose each tag with its quoted sentence, and Gemini Decision 1 for fixed-answer tags (Note: "A thousand questions, one pass"); a person checking a sample. The Note "Seven more flagged" covers Claude reviewing drug-making records.
First step
Run the stock-wording search on the 6,428 letters, read 30 of the hits, and write the tag definitions from what they say.
Done looks like
Every CGMP warning letter from 2018 to 2026 tagged, the tagging rules published, a second person's check of 100 random rows agreeing on at least 95%, and a count by year of letters to owners against letters to contract makers.